Immune-Mediated Hemolytic Anemia

Immune-mediated hemolytic anemia (IMHA) is a serious hematologic disorder in which the immune system aberrantly produces antibodies directed against the cat's own red blood cells (erythrocytes), leading to their premature destruction and resultant anemia [1]. IMHA is categorized as primary (idiopathic), where no underlying cause is identified, or secondary, when it is attributable to an identifiable trigger such as infection, neoplasia, drugs, or vaccines [1]. Although IMHA occurs less commonly in cats than in dogs, it remains a clinically important and potentially life-threatening condition [1][3]. The disease can present acutely and progress rapidly, necessitating prompt diagnosis and aggressive management.

Classification

IMHA is classified as primary (idiopathic) when a comprehensive diagnostic workup fails to identify an underlying cause, or secondary when a specific trigger initiates the immune-mediated erythrocyte destruction [1].

Known Secondary Causes

• ·Infectious diseases: Feline infectious peritonitis (FIP) caused by mutated feline coronavirus is a well-recognized trigger of secondary IMHA in cats [2]. In one study of cats with FIP-associated IMHA, 58% had effusive FIP and 42% non-effusive FIP [2]. Bartonella henselae infection has also been implicated as a cause of secondary IMHA in cats [8]. Feline leukemia virus (FeLV) and Mycoplasma haemofelis (feline hemoplasmosis) are additional infectious etiologies [1][3].
• ·Neoplasia: Lymphoma and other hematologic malignancies may trigger immune-mediated destruction of erythrocytes [1][7].
• ·Drugs and vaccines: Certain drugs and vaccines have been associated with IMHA in cats, though less extensively documented than in dogs [1].
• ·Other immune-mediated diseases: Concurrent immune-mediated thrombocytopenia can occur (Evans syndrome) [1].

Pathological Mechanism

Under normal conditions, the immune system distinguishes self from non-self. In IMHA, this tolerance breaks down, and immunoglobulins (predominantly IgG and/or IgM) and/or complement are directed against antigens on the erythrocyte surface [1][5]. This leads to erythrocyte destruction via two main pathways:

1. ·Extravascular hemolysis: Antibody- and/or complement-coated erythrocytes are recognized and phagocytosed by macrophages in the spleen, liver, and bone marrow — the most common mechanism in cats [1][5].
2. ·Intravascular hemolysis: Complement activation proceeds to completion (membrane attack complex formation), directly lysing erythrocytes within circulation. This results in hemoglobinemia and hemoglobinuria and is associated with more acute and severe presentations [1][5].

Agglutination — the clumping of antibody-coated erythrocytes — can occur when IgM or large amounts of IgG bridge multiple red blood cells, and its presence is a key diagnostic indicator of IMHA [1][3]. The resultant anemia triggers compensatory responses (tachycardia, increased cardiac output), and the release of free hemoglobin and bilirubin from lysed cells leads to icterus and organ dysfunction if severe [5].

Diagnosis of IMHA requires integrating clinical, hematological, and serological findings, while systematically excluding other causes of anemia [1].

Clinical Evaluation

• ·Thorough history including drug administration, vaccination history, travel, and potential infectious disease exposures [1]
• ·Physical examination findings: pallor or icterus, splenomegaly, tachycardia, and signs of thromboembolism (dyspnea, tachypnea) [3][6]

Hematology and Blood Smear

• ·Hematocrit (HCT) / Packed Cell Volume (PCV): Markedly decreased; cats with IMHA commonly present with severe anemia (HCT often <20%, sometimes <15%) [3][7]
• ·Spherocytosis: Spherocytes on blood smear are formed when macrophages partially phagocytose antibody-coated erythrocytes. However, spherocytes can be difficult to identify in cats due to the smaller size of feline erythrocytes and their normal lack of central pallor [1][3]
• ·Reticulocytosis: Regenerative anemia (polychromasia, elevated reticulocyte count) is typical but may be absent in peracute IMHA or when bone marrow response is suppressed [3][5]
• ·Autoagglutination: Gross or microscopic agglutination of erythrocytes in EDTA blood, confirmed by saline dilution test (to distinguish from rouleaux formation), is a strong indicator of IMHA [1][3]
• ·Nucleated red blood cells (nRBCs): May be present as part of the regenerative response [3]
• ·Platelet count (PLT): Thrombocytopenia may co-occur (Evans syndrome) [1]; conversely, thrombocytosis may be seen
• ·White blood cell count (WBC): Neutrophilia/leukocytosis is common, reflecting an inflammatory response and stress [3][7]

Biochemistry Panel

• ·Total bilirubin (TBIL): Elevated due to hemolysis; hyperbilirubinemia and icterus are common [3][5]
• ·ALT: May be elevated secondarily from hepatic hypoxia or erythrophagocytosis [3]
• ·BUN/CREA: Generally within reference range unless concurrent renal compromise exists [3]
• ·Albumin (ALB): May be low in cats with secondary IMHA due to underlying disease (e.g., FIP-associated hypoalbuminemia) [2]
• ·Globulins (GLOB): May be elevated, especially in FIP-associated secondary IMHA where hypergammaglobulinemia is characteristic [2]

Coombs (Direct Antiglobulin) Test

The direct Coombs test (DCT) detects immunoglobulins and/or complement on the erythrocyte surface. In one study, the DCT was positive in 18 of 19 cats with primary IMHA [3]. However, the DCT can yield false negatives (in patients with low antibody levels or following treatment) and false positives (in other inflammatory conditions) [1][3]. The ACVIM consensus recommends that a positive saline agglutination test or positive DCT, in the context of appropriate clinical findings, supports the diagnosis [1].

Diagnostic Imaging

• ·Thoracic radiography and echocardiography: Indicated when dyspnea is present; pulmonary thromboembolism (PTE) is a known complication of IMHA in cats and may demonstrate right-heart enlargement, pulmonary infiltrates, or intracardiac/intravascular thrombi [6]
• ·Abdominal ultrasound: To evaluate splenomegaly, effusion (particularly relevant for FIP), and lymphadenopathy [2][7]

Workup for Secondary Causes

• ·FeLV/FIV testing [1][3]
• ·PCR or serology for Mycoplasma haemofelis, FIP (FCoV antibodies, PCR on effusion), Bartonella species [1][2][8]
• ·Lymph node cytology or biopsy where lymphadenopathy is present [8]
• ·Thorough drug and vaccination history review [1]

Treatment of IMHA in cats involves immunosuppression to halt erythrocyte destruction, management of life-threatening anemia, prevention of thromboembolic complications, and treatment of any identified secondary cause [1][5].

1. Treatment of Underlying Cause (Secondary IMHA)

Identifying and treating the underlying disease is paramount in secondary IMHA. For example:

• ·FIP: Antiviral therapy (e.g., GS-441524 or other nucleoside analogues) targets the underlying coronavirus; resolution of IMHA may follow [2]
• ·Bartonella: Antibiotic therapy (e.g., azithromycin, doxycycline) in combination with immunosuppression has been described [8]
• ·Hemoplasmosis: Doxycycline is the antibiotic of choice for Mycoplasma haemofelis

2. Immunosuppressive Therapy

• ·Glucocorticoids are the cornerstone of IMHA treatment. Prednisolone (2–4 mg/kg/day PO) is typically initiated as first-line immunosuppressive therapy [3][5]. Dexamethasone may be used in severely ill patients who cannot receive oral medications.
• ·Adjunctive immunosuppressants are added when glucocorticoids alone are insufficient or when rapid dose reduction is needed to reduce steroid-related side effects. Agents used in cats include:
  • ·Chlorambucil — commonly used in feline IMHA
  • ·Ciclosporin (cyclosporine) — an alternative option
  • ·Mycophenolate mofetil — used in refractory cases [5]
  • ·Azathioprine — used with extreme caution in cats, as feline thiopurine methyltransferase activity is limited and severe myelosuppression is a significant risk; generally avoided or used at much reduced doses compared to dogs

3. Blood Transfusion and Supportive Care

• ·Packed red blood cell (pRBC) or whole blood transfusion: Indicated for life-threatening anemia (PCV typically <12–15%) or in patients showing hemodynamic instability. Crossmatching is recommended prior to transfusion in cats to minimize transfusion reactions [1][5]
• ·Oxygen therapy: Supplemental oxygen for patients with severe dyspnea or hemodynamic compromise [6]
• ·IV fluid support: To maintain perfusion, correct dehydration, and support renal function; care must be taken to avoid overhydration in severely anemic patients with cardiovascular compromise [5]

4. Antithrombotic Therapy

Thromboembolic complications, including pulmonary thromboembolism, are recognized complications of IMHA in cats [4][6]. The CURATIVE consensus recommends considering antithrombotic prophylaxis in cats with IMHA [4]. Options include:

• ·Low-dose aspirin (e.g., 5 mg/cat every 72 hours)
• ·Clopidogrel — preferred antiplatelet agent in cats
• ·Low molecular weight heparin (LMWH) — may be used in hospitalized or high-risk patients [4] Case reports have documented successful management of PTE secondary to IMHA in cats using echocardiographic monitoring and supportive care [6].

5. Monitoring During Treatment

• ·Serial CBC with reticulocyte counts to track response to therapy [3]
• ·Gradual tapering of immunosuppressives over months once remission is achieved, with close monitoring for relapse [5]

IMHA in cats carries a guarded to poor prognosis, particularly in acute or severe presentations. Survival and prognostic data have been reported in several studies:

• ·In the largest study to date examining primary IMHA in cats (n=72 primary IMHA, n=35 secondary IMHA), overall survival data indicated significant mortality, with prognostic factors for death investigated [7].
• ·In a study of 19 cats with primary IMHA, 16 of 19 cats (84%) survived to discharge from the hospital; however, long-term outcomes were variable, and relapses occurred in some cats [3].
• ·Cats with secondary IMHA may have a worse prognosis dependent on the severity and treatability of the underlying disease [1][7]. For example, FIP-associated IMHA involves an additional disease burden, though modern antiviral therapies for FIP have substantially changed outcomes for FIP itself [2].
• ·Pulmonary thromboembolism secondary to IMHA is a particularly severe complication; successful resolution has been reported in individual cases with prompt echocardiographic diagnosis and aggressive supportive care, but PTE significantly worsens prognosis [6].
• ·Demographic and laboratory prognostic factors: In the study by Swann et al. (2016), various demographic and clinicopathological variables were assessed as potential prognostic factors for mortality in cats with IMHA [7]. Cats requiring blood transfusion, suggesting more severe anemia at presentation, and those with markers of severe disease tend to have higher in-hospital mortality.
• ·Relapse is a recognized concern in primary IMHA; cats that recover may require prolonged immunosuppressive therapy, and disease recurrence upon drug tapering has been reported [3][5].
• ·Overall, short-term (in-hospital) mortality is estimated at approximately 15–30% based on available case series [3][7], though this figure varies by disease severity and underlying cause. Long-term recurrence risk adds to overall morbidity.

There are no definitive evidence-based strategies to prevent primary (idiopathic) IMHA in cats, as the etiology of spontaneous immune dysregulation is not fully understood. However, several practical measures may reduce the risk of secondary IMHA:

• ·Control of infectious diseases: Routine vaccination against FeLV and preventive measures against feline coronavirus exposure (particularly in multi-cat environments) may reduce the risk of secondary IMHA triggered by these infections [1][2]. Testing for FeLV/FIV status is advisable in all cats, as these viruses are established secondary causes [1][3].
• ·Ectoparasite and vector control: Flea control reduces the risk of Bartonella henselae and hemoplasma (Mycoplasma haemofelis) transmission, as these arthropod-borne pathogens are recognized triggers of secondary IMHA [1][8]. Monthly flea preventatives are recommended, particularly in outdoor cats.
• ·Judicious drug use: Care should be taken when prescribing drugs with known potential to trigger immune-mediated reactions; if a drug-associated IMHA is suspected, prompt discontinuation of the offending drug is essential [1].
• ·Vaccine considerations: While vaccines have been implicated in IMHA in dogs, the evidence in cats is less clear; nevertheless, vaccination history should be recorded and considered in the diagnostic workup [1].
• ·Early veterinary evaluation: Prompt investigation of lethargy, pallor, or icterus allows for earlier diagnosis and treatment, which may improve outcomes. There is no evidence that IMHA itself is contagious [1].
• ·Multi-cat household management: Reducing the density of cats and improving hygiene in group housing reduces transmission of FIP-associated coronavirus and hemoplasmas [2].

METADATA